Dr. reddy's laboratories announces the launch of carmustine for injection, usp in the u.s. market

Hyderabad, india & princeton, n.j.--(business wire)--dr. reddy's laboratories ltd. (bse: 500124, nse: drreddy, nyse: rdy, nseifsc: drreddy, along with its subsidiaries together referred to as “dr. reddy's”) today announced the launch of carmustine for injection, usp, a therapeutic equivalent generic version of bicnu® (carmustine for injection) approved by the u.s. food and drug administration (usfda). the bicnu® brand and generic market had u.s. sales of approximately $19.4 million mat for the
RDY Ratings Summary
RDY Quant Ranking